荣昌生物:688331.SH HKEX stock code: 荣昌生物:09995.HK Investors Announcements and Notices Financial Reports Listing Documents 062025.02 An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in th...
RemeGen is led by a visionary management team with an average of more than 20 years of industry experience. They also have proven track records of innovative drug R&D, clinical development and commercialization. We are constituting a professional excellent talent team composed of more than three tho...
2025-01-17 Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment Option for Locally Advanced or Metastatic Urothelial Carcinoma 2025-01-07 2024 SABCS|Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced...
简介:荣昌生物制药 (烟台) 股份有限公司 (曾用名:荣昌生物制药 (烟台) 有限公司) ,成立于2008年,位于山东省烟台市,是一家以从事医药制造业为主的企业。企业注册资本54433.2083万人民币,实缴资本40181.9202万人民币,并已于2022年完成了IPO上市,交易金额26.12亿人民币。通过天眼查大数据分析,荣昌生物制药 (烟台) 股份...
荣昌生物制药(烟台)股份有限公司成立于2008年07月04日,位于中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号,目前处于开业状态,在中国和美国均设有实验研究机构和办事处。荣昌生物致力于发现、开发、生产和商业化同类首创、同类最佳的生物药物,针对自身免疫、肿瘤、眼科等重大疾病领域创制出一批具有重大临床价值...
公司简介 荣昌生物制药是荣昌生物制药(烟台)股份有限公司旗下品牌。荣昌生物制药(烟台)股份有限公司创设于2008年07月04日,公司地址位于中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号,地理条件好;主要经营领域有研发、生产和销售医药产品、诊断试剂产品,以及进行与上述产品及其研发相关的技术服务、技术转让,货物...
荣昌生物是一家始终坚持创新、不断追求科学卓越的公司。在这样一个机遇与挑战并重的平台上,每个人都能够得到足够的尊重与信任。它的开放与包容能够吸引更多优秀人才的加入,海内外业务的扩展,让我有更多机会深入了解行业。同时也让我看到周围更多优秀的同事,他们怀抱激情和理想,始终以专业的态度对待各项工作,散发各自的闪...
In recent years, breakthrough has been made in the treatment of SLE. At this seminar, Professor Mu Rong from Peking University Third Hospital presented the clinical exploration of biological agents as first-line treatments of SLE. The part was chaired by Professor Huang Feng from the First Medic...
荣昌生物是一家专注于生物药物研发及产业化的制药企业,聚焦原研生物新药,追求全球最新。一切发展围绕自主创新,在国内外生物制药领域始终独树一帜。 2013年有幸加盟荣昌生物,从此迈入真核生物表达的生物药质量管理领域。我从一名普通职员做起,工作中每次遇到困难,总有来自瑞典、美国等质量管理专家答疑解惑,每次都会从意识...